USP44 and cancer: This finding is similar to those described in previous reports about pancreatic and colorectal cancers, in which USP44 was found to be downregulated in patients with pancreatic ductal adenocarcinoma and colorectal cancer [20, 21], suggesting that USP44 is a prognostic marker in patients with cancer.